Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
CONCLUSIONS: Evidence concerning the efficacy and safety of glucose-lowering agents in diabetes and CKD is limited. SGLT2 inhibitors and GLP-1 agonists are probably efficacious for glucose-lowering and DPP-4 inhibitors may be efficacious for glucose-lowering. Additionally, SGLT2 inhibitors probably reduce BP, heart failure, and hyperkalaemia but increase genital infections, and slightly increase creatinine. The safety profile for GLP-1 agonists is uncertain. No further conclusions could be made for the other classes of glucose-lowering agents including insulin. More high quality studies are required to help guide therapeutic choice for glucose-lowering in diabetes and CKD.
PMID: 30246878 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S Tags: Cochrane Database Syst Rev Source Type: research
More News: Actos | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Conferences | Databases & Libraries | Diabetes | Dialysis | Endocrinology | Gastroenterology | General Medicine | Glipizide | Heart | Heart Failure | Heart Transplant | Insulin | Januvia | Kidney Transplant | Kidney Transplantation | Liver | Liver Transplant | Orthopaedics | Pancreas | Pancreatic Cancer | Pancreatitis | Respiratory Medicine | SGLT2 Inhibitors | Sodium | Study | Transplant Surgery | Transplants | Urinary Tract Infections | Urology & Nephrology